8Catalona WJ,Smith DS,Ratliff TL,et al.Measurement of prostate-specific antigen in serum as a screening test for prostate cancer[J].N Engl J Med,1991,324(17):1156-61.
9Sardana G,Dowell B,Diamandis EP.Emerging biomarkers for the diagnosis and prognosis of prostate cancer[J].Clin Chem,2008,54(12):195-160.
3Halder S, Chintapalli J, Croce CM. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells [J]. Cancer Res, 1996, 56(5): 1253-5.
4Muenchen HJ, Quigley MM, Pilat MJ. The study of gemcitabine in combination with other chemotherapeutic agents as an effective treatment for prostate cancer [J]. Anticancer Res, 2000, 20(2A):735-40.
5DiPaola RS, Rubin E, Toppmeyer D. Gemcitabine combined with sequential paclitaxel and carboplatin in patients with urothelial cancers and other advanced malignancies[J]. Med Sci Monit, 2003, 9(2): 5-11.
6Jordan MA, Wendell K, Gardiner S. Mitotic block induced in hela cells by low concentrations of paclitaxel results in abnormal mitotic exit and apoptotic cell death [ J ]. Cancer Res, 1996, 56(4): 814-25.
7Ricotti L, Tesei A, De Paola F. In vitro schedule-dependent interaction between docetaxel and gemcitabine in human gastric cancer cell lines[J]. Clin Cancer Res, 2003, 9(2): 900-5.
8Hochhauser D, Schnieders B, Ercikan-Abali E. Effect ofcyclin D1 over expression on drug sensitivity in a human fibrosarcoma cell line[ J ]. J Natl Cancer Inst, 1996, 88(6): 1269-75.
9Panvichian R, Orth K, Pilat MJ. Signaling network of paclitaxel-induced apoptosis in the LNCaP prostate cancer cell line [ J ]. Urology,1999, 54(5): 746-52.
10Sadar MD, Akopian VA, Beraldi E. Characterization of a new in vivo hollow fiber model for the study of progression of prostate cancer to androgen independence[J]. Mol Cancer Ther, 2002, 1 (8): 629-37.
